Your browser doesn't support javascript.
loading
Breast reconstruction after mastectomy: does it decrease depression at the long-term?
de Raaff, Christel Aurora Louise; Derks, Eveline Anne-Jet; Torensma, Bart; Honig, Adriaan; Vrouenraets, Bartholomeus Cornelius.
Afiliação
  • de Raaff CA; Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands ;
  • Derks EA; Department of Anesthesiology, LU Medical Center, Leiden, the Netherlands ;
  • Torensma B; Department of Clinical Epidemiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands ;
  • Honig A; Department of Psychiatry, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands;; Department of Psychiatry, VU Medical Center, Amsterdam, the Netherlands.
  • Vrouenraets BC; Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands ;
Gland Surg ; 5(4): 377-84, 2016 Aug.
Article em En | MEDLINE | ID: mdl-27563558
ABSTRACT

BACKGROUND:

Depression is associated with breast cancer survivors in 22%. Although breast reconstruction (BR) is intended to provide psychological improvements such as reducing depression, literature is inconclusive and without long-term follow-up. The objective is to evaluate the impact of BR after breast cancer related mastectomy on the long-term depression risk and assess predictive factors for depression.

METHODS:

Women who underwent a curative mastectomy between 1999 and 2009 were included. After a mean follow-up of more than 6 years after operation, the Beck Depression Inventory-13 (BDI-13) evaluated depressive symptoms. Multivariable regression analysis provided predictors for depression.

RESULTS:

A total of 139 patients, 34 (24.5%) with and 105 (75.5%) without BR, were analyzed. Seventy-seven patients (48.2%) were at high risk for mild (n=58), moderate (n=5) or severe (n=4) depression. There was a trend for slightly better BDI-13 outcomes for women who underwent BR (2 vs. 4; P=0.06). Living alone [odds ratio (OR) 2.16; P=0.04], low educational level (OR 3.70; P<0.01) and adjuvant hormonal/endocrine-therapy (OR 2.36; P=0.02) were associated with an increased depression risk.

CONCLUSIONS:

BR has no clear influence on depressive symptoms on the long-term. Predictive factors should alert clinicians to assess depressive symptoms in specific breast cancer patients during follow-up.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article